Barnwell Industries, Inc. Adopts Limited-Duration Shareholder Rights Plan Designed to Prevent “Creeping” Control by 30% Shareholder and Protect the Long-Term Value for All Shareholders HONOLULU, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Barnwell Industries, Inc. (NYSE American: BRN) (“Barnwell” or the “Company”) today announced that the Board of Directors (the “Board”) of Barnwell has adopted a limited-duration shareholder rights plan (“Rights Plan”) designed to protect the interests of the Company and all of its shareholders. The Rights Plan is also intended to provide the Board sufficient tim...
180 Degree Capital Corp. and Mount Logan Capital Inc. Announce Agreement to Merge in All-Stock, Transformative Transaction Establishing a US-Exchange Listed Alternative Asset Management and Insurance Solutions Platform with Over $2.4 Billion in Assets Under Management 180 Degree Capital Shareholders to Receive Full Net Asset Value (“NAV”) at Closing in Stock of the Merged Company Support secured from approximately 20% of 180 Degree Capital and 23% of Mount Logan shareholders through voting agreements with additional indicative support from certain other shareholders Combined company will ...
A director at Opko Health Inc bought 500,000 shares at 1.482USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13-16, 2025 at Westin St. Francis hotel in San Francisco. Management will be hosting one-on-one meetings with investors and will be presenting on Wednesday, January 15th at 3:00 p.m. Pacific time. The presentation will be webcast live and available for replay in the Investors section of OPKO Health’s website . About...
Cassava Sciences Provides a Business Update Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment including a workforce reduction of approximately 33% Approximately $128.6 million cash and cash equivalents at December 31, 2024 (unaudited) AUSTIN, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatme...
OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with several types of cancer and multiple sclerosisThere are no current treatments or vaccines for EBVFirst participant dosed with novel investigational EBV vaccine targeting multiple viral proteins in Phase I study WESTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), announces dosing of the first participant in ...
180 Degree Capital Corp. Responds to Letter from Marlton Partners MONTCLAIR, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- 180 Degree Capital Corp. (“180 Degree Capital” or the “Company”) (NASDAQ:TURN) today announced that it has received the press release issued, and the notice of nomination submitted, by Marlton Partners L.P. (“Marlton”) on December 17, 2024. “We believe that the press release issued by Marlton contains a number of inaccuracies and distortions, and we look forward to addressing the points noted in that press release in due time and, if and when appropriate, engaging with...
Barnwell Industries, Inc. Reports Results for its Fourth Quarter and Year Ended September 30, 2024 Success of Twining Drilling Program Continues While OptimizationProjects Maintain Production Levels and Reduce Operating Costs HONOLULU, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Barnwell Industries, Inc. (NYSE American: BRN) today reported financial results for its fourth quarter and year ended September 30, 2024. The Company had revenue of $4,268,000 and a net loss of $1,883,000 or $0.19 per share for the fourth quarter and had revenue of $21,724,000 and a net loss of $5,565,000 or $0.56 per shar...
180 Degree Capital Corp. Notes Average Discount of Net Asset Value per Share to Stock Price for Eleventh Month of Initial Measurement Period of Its Discount Management Program MONTCLAIR, N.J., Dec. 02, 2024 (GLOBE NEWSWIRE) -- 180 Degree Capital Corp. (“180 Degree Capital”) (NASDAQ: TURN), noted today that the average discount between its estimated daily net asset value per share (“NAV”) and its daily closing stock price during November 2024 and year-to-date through the end of November 2024, were approximately 21% and 20%, respectively.1 This discount was approximately 26% on November 29,...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Eaton Vance Limited Duration Income Fund and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 21 November 2024 in which we reassessed the appropriateness of the...
180 Degree Capital Notes Its Portfolio Company Brightcove, Inc., Entered into an Agreement to be Acquired by Bending Spoons MONTCLAIR, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- 180 Degree Capital Corp. (NASDAQ:TURN) (“180 Degree Capital”), is pleased to note that its portfolio company, Brightcove, Inc. (BCOV), announced yesterday that it has entered into a definitive agreement to be acquired by Bending Spoons for approximately $233 million, or $4.45 per share. Prior to this announcement, 180 Degree Capital owned approximately 1.35 million shares of BCOV. “We would like to congratulate Marc...
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease in the ReThink-ALZ Phase 3 study Simufilam continued to demonstrate an overall favorable safety profile Cassava intends to present the data at an upcoming medical meeting The Company will hold a webcast today, November 25, 2024, at 8:00 AM ET AUSTIN, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Comp...
Cassava Sciences to Hold Corporate Update on November 25th Webcast planned for Monday, November 25th at 8:00 AM ET AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s disease, today announced it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. Eastern Time. Event Details: Date: Monday, November 25th Time: 8:00 a.m. Eastern Time Webcast: A replay of the audio webcast will also be available on the Company P...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.